LAWRENCE, Mass., Oct. 9, 2012 /PRNewswire/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the third quarter ended September 30, 2012 on Thursday, November 8, 2012 before the opening of the financial markets.
NxStage will also host a conference call at 9:00 a.m. Eastern Time on Thursday, November 8, 2012 to discuss its third quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international). The call will also be webcast LIVE and can be accessed via the investor relations section of the Company’s website at www.nxstage.com.
A replay of the conference call will be available 2 hours after the completion of the call through November 15, 2012. To access the replay dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 39189975. An online archive of the conference call can be accessed via the investor relations section of the Company’s website at www.nxstage.com.
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at www.nxstage.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward- looking statements. The forward-looking statements in this release include NxStage’s plan to release its financial results on November 8, 2012. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, unexpected difficulty in closing the company’s financial books for the quarter and other factors that are discussed in NxStage’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Kristen K. Sheppard, Esq.
VP, Investor Relations
SOURCE NxStage Medical, Inc.